RETA
Triple agonist targeting GIP, GLP-1, and glucagon receptors. In a phase 2 trial of 338 adults with obesity, the 12 mg dose produced a least-squares mean weight change of -24.2% at 48 weeks versus -2.1% on placebo.
Regulatory status (as of Sept 2026)
Investigational only - no FDA approval for any indication. Not a compoundable substance: it is not on the 503A bulks list, and it was not among the April 2026 Category 2 removals or the July 2026 PCAC votes. Compounded or grey-market 'retatrutide' is unapproved.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Retatrutide is an investigational drug in late-stage (phase 3) human trials. Triple agonist targeting GIP, GLP-1, and glucagon receptors.
| Half-life | About 6 days |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Phase 3 |
| Dosing | Published research: 1, 4, 8 or 12 mg subcutaneously once weekly for 48 weeks in a phase 2 double-blind placebo-controlled trial… details1, 4, 8 or 12 mg subcutaneously once weekly for 48 weeks in a phase 2 double-blind placebo-controlled trial of 338 adults with obesity (escalation from 2 mg or 4 mg starting doses)Community-reportedCommunity-reported: 1–12 mg weekly, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It acts on three gut-hormone receptors (GIP, GLP-1 and glucagon) and led to weight loss in a clinical trial. Agonist of the GIP, GLP-1 and glucagon receptors (Jastreboff 2023). Its effect on body weight comes from a 48-week phase 2 RCT in 338 adults with obesity, in which mean weight change at 48 weeks ranged from -8.7% (1 mg) to -24.2% (12 mg) vs -2.1% with placebo (Jastreboff 2023).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, Retatrutide is typically run at 1–12 mg weekly (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Retatrutide | ~6 days | Subcutaneous injection | Phase 3 |
| 5-Amino-1MQ | Unknown | Oral | Preclinical (animal) |
| AOD-9604 | No published PK data found | Subcutaneous injection | Discontinued |
| Adipotide (FTPP) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| Dulaglutide | ~5 days | Subcutaneous injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Metabolic category. View All Metabolic Peptides
From Our Affiliated Clinic
1836 Wellness offers physician-supervised medical weight loss in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
Learn about medical weight loss →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.